Exelixis, Inc. - Common Stock (EXEL)

64.63
-1.20 (-1.82%)
NASDAQ · Last Trade: Nov 21st, 2:38 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Exelixis Eyes Q1 Zanza Data as It Plans Beyond CABOmarketbeat.com
Exelixis (NASDAQ:EXEL) is preparing for a transition from a company built around its CABO franchise to one with multiple products, as it advances seven pivotal studies of Zanza and weighs additional development opportunities, Chief Strategy Officer Andrew Peters said at the Jefferies London Healthca
Via MarketBeat · November 18, 2026
Where Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change Everythingfool.com
Exelixis’ leading pipeline candidate is inching closer to approval.
Via The Motley Fool · November 16, 2026
Exelixis Has 2 Major Catalysts Coming by March 2027. Here's What Investors Should Watch.fool.com
These catalysts could impact growth down the road.
Via The Motley Fool · November 13, 2026
Exelixis (NASDAQ:EXEL) Q3 Earnings Beat, Revenue In Line as Guidance Holdschartmill.com
Via Chartmill · October 29, 2026
Exelixis (NASDAQ:EXEL): A Quality Stock With Durable Returns on Capitalchartmill.com
Via Chartmill · October 12, 2026
Exelixis (NASDAQ:EXEL) Flashes Strong Technicals and Tight Breakout Setupchartmill.com
Via Chartmill · October 5, 2026
Exelixis (NASDAQ:EXEL): A Value Stock Backed by Strong Fundamentalschartmill.com
Via Chartmill · August 22, 2026
Exelixis (NASDAQ:EXEL) Shows Strong Breakout Setup with Perfect Technical Ratingchartmill.com
Via Chartmill · August 6, 2026
Exelixis Nears FDA Decision, Key Kidney Cancer Data for Zanzalintinibmarketbeat.com
Exelixis (NASDAQ:EXEL) is preparing for a regulatory decision on its cancer drug candidate zanzalintinib and expects results from a kidney cancer study in the first quarter of next year, Chief Strategy Officer Andrew Peters said at an investor event. Peters described the company as approaching a tr
Via MarketBeat · November 11, 2026
Exelixis Bets on Zanza as Next Cancer Franchise as FDA Decision Nearsmarketbeat.com
Exelixis (NASDAQ:EXEL) is working to build its next cancer drug franchise around zanzalintinib, or zanza, while continuing to grow its established CABO business, Chief Strategy Officer Andrew Peters said at a conference discussion with Guggenheim biotech analyst Michael Schmidt. Peters described th
Via MarketBeat · November 11, 2026
The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitationfool.com
These are among the best the industry has to offer.
Via The Motley Fool · November 8, 2026
Exelixis (NASDAQ:EXEL) Posts Mixed Q2: EPS Beats, Revenue Misses, Guidance Loweredchartmill.com
Via Chartmill · August 5, 2026
Exelixis Inc. (NASDAQ:EXEL): A Decent Value Play in the Biotechnology Sectorchartmill.com
Via Chartmill · July 1, 2026
Exelixis Inc (NASDAQ:EXEL) Offers Decent Value with Strong Profitability and Financial Healthchartmill.com
Via Chartmill · June 9, 2026
Exelixis (EXEL) Q3 2026 Earnings Call Transcriptfool.com
Cabozantinib sales grew 11% year over year as zanzalintinib advances toward FDA decisions.
Via The Motley Fool · October 30, 2026
What Exelixis (EXEL) Said on Its Q3 Earnings Callmarketbeat.com
Exelixis (NASDAQ:EXEL) reported third-quarter 2026 revenue of approximately $659 million, supported by continued growth in its cabozantinib franchise and progress toward a potential launch of zanzalintinib in colorectal cancer. Chief Executive Officer Mike Morrissey said the company is positioning
Via MarketBeat · October 29, 2026
Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stockmarketbeat.com
Bristol-Myers Squibb's iza-bren cut breast cancer progression risk by up to 38% in a Phase 3 trial, lifting shares and raising implications for rivals like Exelixis.
Via MarketBeat · October 26, 2026
Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buyfool.com
Exelixis will have to wait longer than expected to earn approval for a new drug. It's not the end of the world.
Via The Motley Fool · October 24, 2026
Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3Bmarketbeat.com
Exelixis (NASDAQ:EXEL) President and CEO Michael Morrissey said the company is focused on expanding its oncology franchises through internal development, selective business development and potential collaborations, while preparing for a planned launch of zanzalintinib in metastatic colorectal cancer
Via MarketBeat · September 17, 2026
Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdlemarketbeat.com
Exelixis (NASDAQ:EXEL) executives outlined plans to continue expanding the CABOMETYX franchise while preparing for a potential launch of zanzalintinib, or zanza, in colorectal cancer later this year. Speaking at a Wells biotech session, Chief Financial Officer Chris Senner said the company is worki
Via MarketBeat · September 15, 2026
Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer Franchisesmarketbeat.com
Exelixis (NASDAQ:EXEL) executives outlined a franchise-focused growth strategy centered on expanding CABOMETYX across renal cell carcinoma and neuroendocrine tumors while advancing zanzalintinib through multiple late-stage studies. Speaking at a company event, Andrew Peters, Exelixis’ senior vice p
Via MarketBeat · September 14, 2026
Exelixis (EXEL) Q2 2026 Earnings Call Transcriptfool.com
Cabozantinib revenue grew 10%, while zanzalintinib advances toward FDA decision in December.
Via The Motley Fool · August 12, 2026
Exelixis Q2 Earnings Call Highlightsmarketbeat.com
Exelixis (NASDAQ:EXEL) reported second-quarter 2026 revenue of approximately $629 million, including $573 million in cabozantinib franchise net product revenue, as the company prepared for a potential late-year launch of zanzalintinib in colorectal cancer and advanced a broader development program f
Via MarketBeat · August 5, 2026
These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside Aheadfool.com
They are riding strong tailwinds that could lift them higher.
Via The Motley Fool · July 24, 2026
3 Under-the-Radar Stocks to Buy and Holdfool.com
Sometimes, little-known stocks are worth buying.
Via The Motley Fool · July 10, 2026